Why the study?
Does intracoronary brachytherapy reduce death, myocardial infarction, and target vessel revascularization in patients with in-stent restenosis compared to placebo?
Does intracoronary brachytherapy reduce death, myocardial infarction, and target vessel revascularization in patients with in-stent restenosis compared to placebo?
Intracoronary brachytherapy is an effective treatment for various forms of in-stent restenosis, reducing hard clinical endpoints, though it requires prolonged dual antiplatelet therapy to prevent late vessel thrombosis.
Answers are grounded in this paper and cite their sources.
Supports brachytherapy for in-stent restenosis; leaves open its role versus modern therapies in prospective trials.
Randomized, double-blind, placebo-controlled trials have demonstrated that intracoronary brachytherapy is more efficacious than placebo in reducing death, myocardial infarction, and target vessel revascularization at long-term follow up of patients with in-stent restenosis. Intracoronary brachytherapy is efficacious in treating totally occluded in-stent restenotic lesions, in treating de novo and in-stent restenotic lesions in saphenous vein grafts, in treating diffuse in-stent restenosis, in treating native coronary ostial in-stent restenotic lesions, in treating patients with diabetes with in-stent restenosis, in treating patients at high-risk for recurrence of restenosis, in treating elderly patients, and in treating patients who failed intracoronary radiation. Beta and gamma intracoronary brachytherapy are equally effective in treating in-stent restenosis. Long-term aspirin and clopidogrel should be administered for at least 1 year to reduce late vessel thrombosis. Inadequate radiation may cause edge stenosis.
No takes yet. Share an insight, caveat, or question.
Saleem et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: